Clinical characteristics and treatment outcomes in patients with liver cirrhosis and lymphoma

Table 1 Baseline characteristics of the study population, n (%)

General characteristics	Cases (n = 10)	Controls (n = 20)
Female sex	6 (60)	12 (60)
Age (yr)	56 ± 14.2	57 ± 12.9
BMI (kg/m2)	25.57 ± 3.44	27.30 ± 7.57
Lymphoma type
Hodgkin lymphoma	1 (10)	2 (10)
Non-Hodgkin lymphoma	9 (90)	18 (90)
Laboratory data
Hemoglobin (g/dL)	12.13 ± 2.39	11.97 ± 3.18
Platelets (K/μL)	166.60 ± 143.8a	293.9 ± 157.6
Leukocytes (K/μL)	5.4 ± 1.79	7.47 ± 3.79
INR	1.24 ± 0.19b	1.0 ± 1.0
Total bilirubin (mg/dL)	1.74 ± 1.31a	0.97 ± 0.75
Direct bilirubin (mg/dL)	0.76 ± 0.82a	0.27 ± 0.34
ALT (U/L)	31.82 ± 33.30	25.6 ± 13.35
AST (U/L)	48.50 ± 27.31a	32.1 ± 16.52
Alkaline phosphatase (U/L)	210.40 ± 261.2	136.40 ± 149.1
Albumin (g/dL)	2.78 ± 0.69	3.3 ± 0.82
Sodium (mmol/L)	132 (130-138)	137 (132-140)
Creatinine (mg/dL)	0.82 ± 0.21	1.63 ± 2.25
β-2 Microglobulin (g/dL)	3.17 ± 1.39	3.02 ± 3.08
LDH (U/L)	198.29 ± 119.81	356.5 ± 304.86
Comorbidities
Obesity	2 (20)	6 (30)
Dyslipidemia	0 (0)	4 (20)
Diabetes mellitus	3 (30)	3 (15)
Arterial hypertension	2 (20)	8 (40)
Alcohol consumption	3 (30)	5 (25)
Tobacco consumption	5 (50)	7 (35)
Rheumatoid arthritis	0 (0)	2 (10)

mean ± SD, median (p25-p75), absolute frequencies (%);

^aP < 0.05 vs controls,

^bP < 0.01 vs controls. BMI: Body mass index; INR: International normalized ratio; ALT: Alanine transaminase; AST: Aspartate transaminase; β-2 Microglobulin: Beta-2 microglobulin; LDH: Lactic dehydrogenase.